Short answer: amycretin is one molecule that does two jobs — a Novo Nordisk unimolecular agonist that activates both the amylin and GLP-1 receptors. Its headline feature is format: Novo is developing it as both a once-daily oral tablet and a once-weekly injection. A Phase 2 trial in type-2 diabetes reported up to ~14.5% weight loss (subcutaneous) and ~10.1% (oral); earlier obesity Phase 1 data drew attention for the scale of reduction over a short period. It has no marketing authorisation anywhere as of mid-2026, with Phase 3 planned. New-U does not sell amycretin. Part of our next obesity-research wave overview.
Plain-English summary. Amycretin is an unapproved, investigational Novo Nordisk molecule. The FDA, MHRA and EMA have not authorised it. This page is general information, not legal or medical advice; do not use unapproved compounds on people.
Amycretin is a unimolecular agonist — a single engineered molecule that hits two receptors at once: the amylin receptor and the GLP-1 receptor. That is the same two-pathway idea behind CagriSema, but achieved inside one molecule rather than by combining two. The single-molecule approach is what makes an oral formulation realistic.
Novo is developing amycretin in two formats, which is unusual and strategically deliberate:
For the broader oral-vs-injectable question across the class, see our explainer on oral vs injectable GLP-1 research.
The two pathways are complementary, not redundant:
Stacking them in a single molecule means one pharmacokinetic profile to manage instead of two, and one manufacturing stream — a simplification that matters at population scale.
The subcutaneous Phase 1b/2a results were published in The Lancet (2025). The most concrete efficacy readout to date is the Phase 2 trial in type-2 diabetes (n=448, patients inadequately controlled on metformin with or without an SGLT2 inhibitor):
| Formulation | Weight loss vs placebo | Population |
|---|---|---|
| Once-weekly subcutaneous | up to ~−14.5% (placebo ~−2.6%) | Type-2 diabetes Phase 2 |
| Once-daily oral | up to ~−10.1% (placebo ~−2.5%) | Type-2 diabetes Phase 2 |
Mean baseline weight in that trial was ~101.1 kg, and HbA1c fell significantly alongside weight. Adverse events were predominantly gastrointestinal and mostly mild-to-moderate, consistent with the incretin and amylin classes. Novo Nordisk has stated it plans to initiate Phase 3 trials across multiple indications.
A note on the numbers. Weight-loss percentages are not comparable across trials with different populations and durations. The diabetes population above typically loses less weight than an obesity-only cohort, so amycretin’s obesity-trial figures may read differently. Treat each number as belonging to its specific trial.
| Compound | Mechanism | Format | Status |
|---|---|---|---|
| Amycretin | Amylin + GLP-1 (one molecule) | Oral & injectable | Phase 3 planned |
| CagriSema | Amylin + GLP-1 (two molecules) | Injectable | NDA filed |
| Petrelintide | Amylin only | Injectable | Phase 3 planned |
| Orforglipron | GLP-1 (small molecule) | Oral | Submissions filed |
Amycretin is a proprietary Novo Nordisk molecule, not a catalogued reference peptide. New-U does not sell amycretin. The established, verifiable research references covering its two pathways are:
Each ships as a sealed, lyophilised reference peptide verified to >99% HPLC purity with a per-batch Certificate of Analysis — research use only, not for human consumption.
What is amycretin?
A Novo Nordisk unimolecular agonist of the amylin and GLP-1 receptors, in oral and injectable development.
Is amycretin approved?
No. As of mid-2026 it has no marketing authorisation; Phase 3 is planned.
How much weight loss?
Up to ~14.5% (SC) and ~10.1% (oral) in a Phase 2 diabetes trial; obesity-cohort figures differ.
Why not just use CagriSema?
Amycretin packs both activities into one molecule, enabling an oral tablet — a two-peptide combination cannot easily do that.
Can I buy amycretin for research?
No — it is proprietary. New-U catalogues the amylin and GLP-1 references (cagrilintide, semaglutide) instead. Research use only.
External links are provided for research reference only; New-U is not affiliated with the cited organisations and links carry no endorsement either way.
New-U Research Compounds catalogues cagrilintide and semaglutide — the amylin and GLP-1 research references — as sealed 10-vial packs of lyophilised reference peptide, independently verified by Janoshik and Freedom Diagnostics for >99% HPLC purity, with a per-batch Certificate of Analysis. Research use only — not for human consumption.
Browse GLP-1 & metabolic compounds